Filana Therapeutics, Inc
NASDAQ:FLNA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Filana Therapeutics, Inc
PP&E Gross
Filana Therapeutics, Inc
PP&E Gross Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Gross | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Filana Therapeutics, Inc
NASDAQ:FLNA
|
PP&E Gross
$20.6m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
PP&E Gross
$24.5B
|
CAGR 3-Years
7%
|
CAGR 5-Years
6%
|
CAGR 10-Years
4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
PP&E Gross
$9.1B
|
CAGR 3-Years
7%
|
CAGR 5-Years
6%
|
CAGR 10-Years
8%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
PP&E Gross
$19.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
PP&E Gross
$25.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
PP&E Gross
$24.7B
|
CAGR 3-Years
34%
|
CAGR 5-Years
23%
|
CAGR 10-Years
12%
|
|
Filana Therapeutics, Inc
Glance View
Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures. The Company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.
See Also
What is Filana Therapeutics, Inc's PP&E Gross?
PP&E Gross
20.6m
USD
Based on the financial report for Dec 31, 2025, Filana Therapeutics, Inc's PP&E Gross amounts to 20.6m USD.
What is Filana Therapeutics, Inc's PP&E Gross growth rate?
PP&E Gross CAGR 3Y
-4%
Over the last year, the PP&E Gross growth was -2%. The average annual PP&E Gross growth rates for Filana Therapeutics, Inc have been -4% over the past three years .
